Stryker (SYK) Expected to Post Earnings on Thursday

Stryker (NYSE:SYK) is expected to post its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Stryker to announce earnings of $3.49 per share and revenue of $6.5802 billion for the quarter. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.84 EPS. On average, analysts expect Stryker to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Stryker Trading Up 2.1%

SYK opened at $337.31 on Tuesday. The stock has a market capitalization of $129.31 billion, a PE ratio of 39.04, a P/E/G ratio of 2.12 and a beta of 0.77. The firm’s fifty day moving average price is $315.18 and its 200 day moving average price is $335.37. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker has a 12-month low of $281.00 and a 12-month high of $404.14.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Insiders Place Their Bets

In related news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president owned 10,582 shares in the company, valued at approximately $3,247,298.34. This trade represents a 30.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 323,264 shares of company stock valued at $100,659,489. Company insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Stryker

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Schnieders Capital Management LLC. acquired a new stake in Stryker in the second quarter worth $205,000. Brighton Jones LLC lifted its stake in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after buying an additional 609 shares during the last quarter. Greenline Wealth Management LLC acquired a new position in shares of Stryker during the fourth quarter valued at $113,000. Triumph Capital Management acquired a new position in shares of Stryker during the third quarter valued at $103,000. Finally, Strive Financial Group LLC bought a new position in shares of Stryker during the fourth quarter worth about $93,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of recent analyst reports. UBS Group restated a “buy” rating on shares of Stryker in a research note on Tuesday. Leerink Partners decreased their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Canaccord Genuity Group lowered their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Needham & Company LLC lowered their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $392.52.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.